Article
Hematology
Govindarajan Thangavelu, Chao Wang, Michael Loschi, Asim Saha, Mark J. Osborn, Scott N. Furlan, Kazutoshi Aoyama, Cameron McDonald-Hyman, Ethan G. Aguilar, Amanda S. Janesick, Roshantha A. Chandraratna, Yosef Refaeli, Angela Panoskaltsis-Mortari, Kelli P. MacDonald, Geoffrey R. Hill, Robert Zeiser, Ivan Maillard, Jonathan S. Serody, William J. Murphy, David H. Munn, Bruce Blumberg, Chrysothemis Brown, Vijay Kuchroo, Leslie S. Kean, Keli L. Hippen, Randolph J. Noelle, Bruce R. Blazar
Summary: IRX4204, a novel RXR agonist, shows promising results in inhibiting acute GVHD by suppressing T-cell proliferation, reducing Th1 differentiation, and promoting Treg generation. It also reduces intestinal injury, decreases inflammatory cytokine levels, and enhances Treg stability and generation. Despite favoring Tregs, IRX4204-treated recipients maintain graft-versus-leukemia responses against leukemia and lymphoma cells.
Article
Oncology
Arnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, Emanuele Angelucci, Boris Afanasyev, Jan J. Cornelissen, Simona Sica, Ellen Meijer, Fabio Ciceri, Gwendolyn Van Gorkom, Nicolaus Kroger, Hans Martin, Pietro Pioltelli, Antonio Risitano, Jonathan Canaani, Bipin N. Savani, Jaime Sanz, Mohamad Mohty
Summary: In the setting of PTCy for patients with acute leukemia, haplo bone marrow transplantation resulted in a lower incidence of GvHD compared with UD mobilized peripheral blood stem cell transplantation. However, differences in GvHD did not affect overall survival outcomes, suggesting both donor sources are equally acceptable for allo-HCT.
CLINICAL CANCER RESEARCH
(2021)
Review
Oncology
Robert Puckrin, Mona Shafey, Jan Storek
Summary: Although the use of allogeneic HCT for CLL has declined, it remains important for high-risk or heavily pretreated patients. The procedure carries risks of GVHD, infection, and NRM, but advancements have made it safer and more effective. This review focuses on evidence-based strategies to maximize benefit and minimize toxicity of allogeneic HCT for CLL.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Oscar B. Lahoud, Sean M. Devlin, Molly A. Maloy, Lindsey E. Roeker, Parastoo B. Dahi, Doris M. Ponce, Boglarka Gyurkocza, Guenther Koehne, James W. Young, Hugo R. Castro-Malaspina, Juliet N. Barker, Esperanza B. Papadopoulos, Ann A. Jakubowski, Andrew D. Zelenetz, Anthony R. Mato, Sergio A. Giralt, Miguel A. Perales, Craig S. Sauter
Summary: This study demonstrates that allogeneic hematopoietic stem cell transplantation (HSCT) can potentially cure patients with chronic lymphocytic leukemia (CLL), with favorable progression-free survival (PFS) and overall survival (OS) rates. The impact of novel agents on HSCT outcomes was found to be negligible. Reduced intensity conditioning (RIC) HSCT may be a successful treatment option for CLL patients with Richter's transformation and poor-risk CLL patients.
Article
Oncology
Amandine Le Bourgeois, Maxime Jullien, Alice Garnier, Pierre Peterlin, Marie C. Bene, Thierry Guillaume, Patrice Chevallier
Summary: This study aimed to assess the feasibility and safety of using PTCY as the sole prophylaxis for GVHD in adult patients. However, the study had to be stopped due to an unacceptable rate of severe acute GVHD. Despite this, overall survival and GVHD-free relapse-free survival remained good.
CLINICAL AND TRANSLATIONAL MEDICINE
(2023)
Review
Immunology
Laura Marie Gail, Kimberly Julia Schell, Piotr Lacina, Johanna Strobl, Steven J. Bolton, Emilie Steinbakk Ulriksen, Katarzyna Bogunia-Kubik, Hildegard Greinix, Rachel Emily Crossland, Marit Inngjerdingen, Georg Stary
Summary: Chronic Graft-versus-Host Disease (cGVHD) is a life-threatening inflammatory condition occurring after allogeneic hematopoietic stem cell transplantation. Despite progress in understanding disease pathogenesis, treatment options remain limited. This review provides an overview of the pathogenic and protective mechanisms involving immune subsets, as well as the emerging field of intercellular communication via extracellular vesicles and its implications for cGVHD research. The importance of understanding aberrant cell communication for biomarker discovery and personalized treatment is discussed.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Premal D. Lulla, Swati Naik, Spyridoula Vasileiou, Ifigeneia Tzannou, Ayumi Watanabe, Manik Kuvalekar, Suhasini Lulla, George Carrum, Carlos A. Ramos, Rammurti Kamble, LaQuisa Hill, Jasleen Randhawa, Stephen Gottschalk, Robert Krance, Tao Wang, Mengfen Wu, Catherine Robertson, Adrian P. Gee, Betty Chung, Bambi Grilley, Malcolm K. Brenner, Helen E. Heslop, Juan F. Vera, Ann M. Leen
Summary: Leukemia-specific T cells (mLSTs) selectively recognized and killed leukemia antigen-pulsed cells in vitro, showing no activity against recipient's normal cells. Infusions of mLSTs were well tolerated with no severe GVHD, leading to antileukemia effects and promising outcomes for AML/MDS patients after HCT.
Article
Immunology
Danielle E. Arnold, Rofida Nofal, Connor Wakefield, Kai Lehmberg, Katharina Wustrau, Michael H. Albert, Emma C. Morris, Jennifer R. Heimall, Nancy J. Bunin, Ashish Kumar, Michael B. Jordan, Theresa Cole, Sharon Choo, Tim Brettig, Carsten Speckmann, Stephan Ehl, Malgorzata Salamonowicz, Justin Wahlstrom, Kanchan Rao, Claire Booth, Austen Worth, Rebecca A. Marsh
Summary: Patients with XIAP deficiency tolerate reduced-intensity conditioning (RIC) and reduced-toxicity conditioning (RTC) regimens well, with survival rates similar to hematopoietic cell transplantation (HCT) for other genetic HLH disorders. Acute GVHD and HLA mismatch negatively impact survival in XIAP-deficient patients undergoing allogeneic HCT.
JOURNAL OF CLINICAL IMMUNOLOGY
(2022)
Article
Hematology
Sanjeev Kumar Sharma, Dharma Choudhary, Divya Doval, Vipin Khandelwal, Amee Patel, Rasika Setia, Tina Dadu, Anil Handoo
Summary: This study compared the long-term outcomes of MAC and RIC allo-HSCT in AML and MDS patients, finding no significant differences in overall survival, relapse-free survival, and non-relapse mortality between the two conditioning regimens. Chronic graft-versus-host disease was the only factor associated with decreased risk of relapse and improved overall survival, regardless of the type of conditioning regimen used.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION
(2021)
Article
Oncology
Marie Bleakley, Alison Sehgal, Stuart Seropian, Melinda A. Biernacki, Elizabeth F. Krakow, Ann Dahlberg, Heather Persinger, Barbara Hilzinger, Paul J. Martin, Paul A. Carpenter, Mary E. Flowers, Jenna Voutsinas, Theodore A. Gooley, Keith Loeb, Brent L. Wood, Shelly Heimfeld, Stanley R. Riddell, Warren D. Shlomchik
Summary: This study evaluated the impact of T-N depletion on chronic GVHD (cGVHD) and other outcomes. The results showed that T-N depletion significantly reduced the incidence of GVHD without increasing the risk of relapse and nonrelapse mortality.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Biophysics
Nobuhiko Imahashi, Seitaro Terakura, Eisei Kondo, Koji Kato, Sung-Won Kim, Akihito Shinohara, Mizuki Watanabe, Takahiro Fukuda, Naoyuki Uchida, Hikaru Kobayashi, Jun Ishikawa, Keisuke Kataoka, Souichi Shiratori, Takashi Ikeda, Ken-ichi Matsuoka, Shuro Yoshida, Tadakazu Kondo, Takafumi Kimura, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Junya Kanda
Summary: The study showed that UCB transplantation with optimal conditioning and GVHD prophylaxis had better outcomes compared to MRD and MUD transplantation, suggesting it is a highly effective treatment for mature lymphoid malignancies. This indicates that UCB transplantation might be preferred over MRD or MUD transplantation in certain settings.
BONE MARROW TRANSPLANTATION
(2022)
Article
Oncology
Brendan Rasor, Tyler Dickerson, Qiuhong Zhao, Patrick Elder, Jonathan E. Brammer, Karilyn Larkin, Samantha Jaglowski, Alice Mims, Sam Penza, Sumithira Vasu, Sarah A. Wall, Basem William, Ayman Saad, Julianna V. F. Roddy, Hannah Choe, Marcin Puto
Summary: The retrospective cohort study compared the efficacy and tolerability of busulfan AUC target of 16.4 mg x Hr/L per day (FluBu4K) and a conventional RIC regimen (FluBu2) in patients with AML or MDS. The results suggest that for select patients, there may be benefit in choosing FluBu4K over FluBu2, as it showed a lower cumulative incidence of relapse at 18 months.
LEUKEMIA & LYMPHOMA
(2021)
Article
Oncology
Juliette Stolze, Marlou Boor, Mette D. Hazenberg, Henk S. Brand, Judith E. Raber-Durlacher, Alexa M. G. A. Laheij
Summary: The study assessed the impact of oral chronic graft-versus-host-disease (cGVHD) symptoms on oral health-related quality of life (OHRQoL). Results showed that OHRQoL was mainly negatively affected by oral pain and sensitivity, rather than the severity of oral mucosal cGVHD. Special attention from healthcare professionals is essential to improve OHRQoL for patients with oral cGVHD.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Ophthalmology
Anahita Kate, Swati Singh, Anthony Vipin Das, Sayan Basu
Summary: This study evaluated the clinical features and management outcomes of dry eye disease (DED) in chronic ocular GvHD following allogenic hematopoietic stem cell transplantation (HSCT). A total of 34 patients (68 eyes) were studied, and aqueous tear deficiency was present in 71% of the eyes. Topical immunosuppression was required in 88% of cases, and improvement in corneal and conjunctival staining scores was noted. The risk of disease progression was greater in eyes with conjunctival hyperemia and severe aqueous deficiency.
INDIAN JOURNAL OF OPHTHALMOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Ethan Strattan, Gerhard Carl Hildebrandt
Summary: HSCT is commonly used for inborn defects or acute leukemias, but is hindered by GVHD. Acute GVHD pathology is understood, but cellular drivers are unclear. Mast cells play a role in immune response and wound healing, possibly contributing to fibrosis in chronic GVHD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Letter
Hematology
Dai Chihara, Luuk Gras, Nienke Zinger, Nicolaus Kroeger, Jiri Mayer, Jakob Passweg, Regis Peffault de Latour, Jenny Byrne, William Krueger, Jan-Paul Bohn, Uwe Platzbecker, Igor Wolfgang Blau, Francesca Bonifazi, Grzegorz Helbig, Andrew McDonald, Martin Mistrik, Mohamad Mohty, Ron Ram, Jaime Sanz, Carlos Vallejo Llamas, Robert J. Kreitman, Patrick J. Hayden, Donal McLornan, Olivier Tournilhac, Michel van Gelder, Ibrahim Yakoub-Agha
Review
Hematology
Razan Mohty, Rama El Hamed, Eolia Brissot, Ali Bazarbachi, Mohamad Mohty
Summary: The treatment of acute myeloid leukemia (AML) has improved with the use of next-generation sequencing and targeted therapies. Allogeneic stem cell transplantation (allo-HCT) remains important for consolidating treatment and reducing relapse risk. Maintenance therapy following allo-HCT can further enhance the anti-leukemia effect without increasing the risk of complications. This paper summarizes novel therapies for AML before, during, and after allo-HCT and reviews ongoing studies.
Article
Hematology
Alexandros Spyridonidis, Myriam Labopin, Bipin Savani, Sebastian Giebel, Gesine Bug, Stefan Schoenland, Nicolaus Kroeger, Matthias Stelljes, Thomas Schroeder, Andrew McDonald, Igor-Wolfgang Blau, Martin Bornhaeuser, Montse Rovira, Wolfgang Bethge, Andreas Neubauer, Arnold Ganser, Jean Henri Bourhis, Matthias Edinger, Bruno Lioure, Gerald Wulf, Kerstin Schaefer-Eckart, Mutlu Arat, Zinaida Peric, Christoph Schmid, Ali Bazarbachi, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: In this registry-based study, the outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) in adult patients with acute lymphoblastic leukemia (ALL) were compared. The study found that the total dose of total body irradiation (TBI) did not influence the survival outcomes for patients, regardless of whether they received a standard 12-Gray or lower 8-Gray dose.
Article
Hematology
Gerard Socie, Dietger Niederwieser, Nikolas von Bubnoff, Mohamad Mohty, Jeff Szer, Reuven Or, James Garrett, Anirudh Prahallad, Celine Wilke, Robert Zeiser
Summary: Systemic steroids are the first-line treatment for acute graft-versus-host disease, but about 50% of patients become steroid-refractory or dependent. Ruxolitinib is the only approved therapy for these patients and has shown superior efficacy compared with the best available therapy in a clinical trial.
Article
Biophysics
Claire Michel, Marie Robin, Stephane Morisset, Didier Blaise, Johan Maertens, Patrice Chevalier, Cristina Castilla-Llorente, Edouard Forcade, Patrice Ceballos, Ibrahim Yakoug-Agha, Xavier Poire, Martin Carre, Jacques-Olivier Bay, Yves Beguin, Michael Loschi, Anne Huynh, Gaelle Guillerm, Sylvie Francois, Jean-Baptiste Mear, Remy Dulery, Felipe Suarez, Karin Bilger, Jerome Cornillon, Yves Chalandon, Natacha Maillard, Helene Labussiere-Wallet, Amandine Charbonnier, Pascal Turlure, Ana Berceanu, Sylvain Chantepie, Sebastien Maury, Ali Bazarbachi, Anne-Lise Menard, Stephanie Nguyen-Quoc, Marie-Therese Rubio, Maud D'Aveni
Summary: Allogeneic hematopoietic stem cell transplantation is the best option for treating higher-risk myelodysplastic syndrome. Patients with monosomal karyotype and/or complex karyotype abnormalities have lower survival rates after transplantation. This study compared outcomes in higher-risk MDS patients who received transplantation from HLA-matched sibling donors, HLA-matched unrelated donors, and HLA haploidentical donors. The results showed that the overall survival was better in the HLA-matched unrelated donor group.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Klaus Hirschbuehl, Myriam Labopin, Emmanuelle Polge, Didier Blaise, Jean Henri Bourhis, Gerard Socie, Edouard Forcade, Ibrahim Yakoub-Agha, Helene Labussiere-Wallet, Wolfgang Bethge, Patrice Chevallier, Sarah Bonnet, Matthias Stelljes, Alexandros Spyridonidis, Zinaida Peric, Eolia Brissot, Bipin Savani, Sebastian Giebel, Christoph Schmid, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: Allogeneic hematopoietic cell transplantation is a curative treatment for high-risk acute lymphoblastic leukemia, and conditioning regimens based on 12 Gray total body irradiation are the standard for patients under 45 years old. However, elderly patients often receive intermediate intensity conditioning to reduce toxicity. A retrospective study compared the outcomes of different conditioning regimens in ALL patients over 45 years old.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Iman Abou Dalle, Myriam Labopin, Nicolaus Kroeger, Thomas Schroeder, Juergen Finke, Matthias Stelljes, Andreas Neubauer, Didier Blaise, Ibrahim Yakoub-Agha, Urpu Salmenniemi, Edouard Forcade, Maija Itala-Remes, Peter Dreger, Gesine Bug, Jakob Passweg, Michael Heuser, Goda Choi, Eolia Brissot, Sebastian Giebel, Arnon Nagler, Fabio Ciceri, Ali Bazarbachi, Mohamad Mohty
Summary: Pre-transplant detectable measurable residual disease (MRD) is still associated with high risk of relapse and poor outcomes in acute myeloid leukemia (AML). The impact of disease burden on prediction of relapse and survival in patients receiving allogeneic hematopoietic cell transplantation (allo-HCT) in first remission (CR1) was evaluated. The study found that patients in CR1 and MRD positive at time of transplant could still be salvaged by allo-HCT, with significantly better outcomes than patients transplanted with active disease.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Arnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, Didier Blaise, Sergey Bondarenko, Jan Vydra, Goda Choi, Montserrat Rovira, Peter Remenyi, Ellen Meijer, Claude Eric Bulabois, J. L. Diez-Martin, Ibrahim Yakoub-Agha, Eolia Brissot, Alexandros Spyridonidis, Jaime Sanz, Amit Patel, Mutlu Arat, Ali Bazarbachi, Gesine Bug, Bipin N. Savani, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty
Summary: In this study, the impact of measurable residual disease (MRD) on the outcomes of post-transplant cyclophosphamide (PTCy)-based allo-HCT in acute myeloid leukemia (AML) patients in first complete remission (CR1) was assessed. The results showed that MRD positive (MRD+) patients had higher relapse rates and lower survival rates compared to MRD negative (MRD-) patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Rama Al Hamed, Maud Ngoya, Jacques-Emmanuel Galimard, Henrik Sengeloev, Tobias Gedde-Dahl, Aleksandr Kulagin, Uwe Platzbecker, Ibrahim Yakoub-Agha, Jenny L. Byrne, Thomas Valerius, Gerard Socie, Nicolaus Kroeger, Didier Blaise, Ali Bazarbachi, Jaime Sanz, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: This retrospective study investigates the impact of time on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes for patients with acute myeloid leukemia (AML) in second complete remission (CR2). The results show that outcomes of allo-HCT in CR2 have significantly improved over time, with the most favorable outcomes achieved with a matched sibling donor (MSD).
Article
Oncology
Michael J. Dickinson, Pere Barba, Ulrich Jaeger, Nirav N. Shah, Didier Blaise, Javier Briones, Leyla Shune, Nicolas Boissel, Attilio Bondanza, Luisa Mariconti, Anne-Laure Marchal, David S. Quinn, Jennifer Yang, Andrew Price, Akash Sohoni, Louise M. Treanor, Elena J. Orlando, Jennifer Mataraza, Jaclyn Davis, Darlene Lu, Xu Zhu, Boris Engels, Laure Moutouh-de Parseval, Jennifer L. Brogdon, Michele Moschetta, Ian W. Flinn
Summary: CAR-T cell product quality and stemness are crucial for treatment efficacy. YTB323, a novel CAR-T cell therapy, showed enhanced in vivo expansion and antitumor activity at lower doses in preclinical and preliminary clinical trials. It also exhibited promising safety and clinical response rates, supporting its continued development for relapsed/refractory diffuse large B-cell lymphoma.
Article
Medicine, General & Internal
Wen-hui Gao, Jia-yan Zhu, Li-ning Wang, Ming Wan, Ling Wang, Raynier Devillier, Jie-ling Jiang, Didier Blaise, Jiong Hu
Summary: The combination of PT-Cy, tacrolimus, and low-dose post-engraftment ATG is a promising graft-versus-host disease (GVHD) prophylaxis strategy for patients undergoing allogeneic stem cell transplantation. This study reports the experience of using this regimen in haplo-identical transplantation, showing low incidence of acute GVHD.
FRONTIERS IN MEDICINE
(2023)
Review
Multidisciplinary Sciences
Huisheng Ai, Nelson J. Chao, David A. Rizzieri, Xiaojun Huang, Thomas R. Spitzer, Jianxiang Wang, Mei Guo, Armand Keating, Elizabeth F. Krakow, Didier Blaise, Jun Ma, Depei Wu, John Reagan, Usama Gergis, Rafael F. Duarte, Preet M. Chaudhary, Kaixun Hu, Changlin Yu, Qiyun Sun, Ephraim Fuchs, Bo Cai, Yajing Huang, Jianhui Qiao, David Gottlieb, Kirk R. Schultz, Mingyao Liu, Xiequn Chen, Wenming Chen, Jianmin Wang, Xiaohui Zhang, Jianyong Li, He Huang, Zimin Sun, Fei Li, Linhua Yang, Liansheng Zhang, Lijuan Li, Kaiyan Liu, Jie Jin, Qifa Liu, Daihong Liu, Chunji Gao, Chuanbo Fan, Li Wei, Xi Zhang, Liangding Hu, Weijing Zhang, Yuyang Tian, Weidong Han, Jun Zhu, Zhijian Xiao, Daobin Zhou, Bolong Zhang, Yongqian Jia, Yongqing Zhang, Xiaoxiong Wu, Xuliang Shen, Xuzhang Lu, Xinrong Zhan, Xiuli Sun, Yi Xiao, Jingbo Wang, Xiaodong Shi, Bo Zheng, Jieping Chen, Banghe Ding, Zhao Wang, Fan Zhou, Mei Zhang, Yizhuo Zhang, Jie Sun, Bing Xia, Baoan Chen, Liangming Ma
Summary: Recent studies have shown that microtransplant (MST) could improve outcome of patients with elderly acute myeloid leukemia (EAML). To further standardize the MST therapy and improve outcomes in EAML patients, the International Microtransplant Interest Group provides recommendations and considerations for MST in the treatment of EAML, based on analysis of the literature on MST, especially MST with EAML from January 1st, 2011 to November 30th, 2022. The recommendations address key issues including therapeutic principle, candidate selection, chemotherapy regimens, post-remission therapy, and other aspects such as donor screening and complications.
Article
Hematology
Mohamed A. Kharfan-Dabaja, Myriam Labopin, Ernesto Ayala, Ali Bazarbachi, Didier Blaise, Jan Vydra, Stefania Bramanti, Maija Itala-Remes, Christoph Schmid, Alessandro Busca, Edouard Forcade, Werner Rabitsch, Marco Zecca, Nicolaus Kroeger, Claude-Eric Bulabois, Giovanni Grillo, Alessandro Rambaldi, Renato Fanin, Francesco Zallio, Nicola Di Renzo, Yener Koc, Yana Novis, Andrew McDonald, Concepcion Herrera Arroyo, Jaime Sanz, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Summary: The study evaluated the impact of HLA mismatches on post-allograft outcomes in haploidentical allo-HCT for acute myeloid leukemia. The results showed that the extent of HLA disparity did not affect the incidence of acute and chronic graft-versus-host disease. Overall survival, leukemia-free survival, and relapse incidence were similar between the groups.
Article
Hematology
Alberto Mussetti, Abraham S. Kanate, Tao Wang, Meilun He, Mehdi Hamadani, Herve Finel, Ariane Boumendil, Bertram Glass, Luca Castagna, Alida Dominietto, Joseph McGuirk, Didier Blaise, Zafer Gulbas, Jose Diez-Martin, Steven G. E. Marsh, Sophie Paczesny, Shahinaz M. Gadalla, Peter Dreger, Mei-Jie Zhang, Stephen R. Spellman, Stephanie J. Lee, Yung-Tsi Bolon, Anna Sureda
Summary: When comparing the outcomes of using a haploidentical donor and a matched unrelated donor (MUD) for lymphoma patients receiving post-transplantation cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis, the study found that MUD had better results in terms of overall mortality, progression-free survival, nonrelapse mortality, platelet engraftment, acute grade 2-4 GVHD incidence, and chronic GVHD. However, there were no significant differences in terms of relapse and neutrophil engraftment. Therefore, if a MUD is available in a timely manner, it should be preferred over a haploidentical donor for lymphoma patients using PTCy-based GVHD prophylaxis.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Alicia Rovo, Luuk Gras, Brian Piepenbroek, Nicolaus Kroeger, H. Christian Reinhardt, Aleksandar Radujkovic, Didier Blaise, Guido Kobbe, Riitta Niityvuopio, Uwe Platzbecker, Katja Sockel, Mathilde Hunault-Berger, J. J. Cornelissen, Edouard Forcade, Jean Henri Bourhis, Yves Chalandon, Francesca Kinsella, Stephanie Nguyen-Quoc, Johan Maertens, Ahmet Elmaagacli, Nicola Mordini, Patrick Hayden, Kavita Raj, Joanna Drozd-Sokolowska, Liesbeth C. de Wreede, Donal P. Mclornan, Marie Robin, Ibrahim Yakoub-Agha, Francesco Onida
Summary: This study compared the outcomes of CMML and MDS patients after hematopoietic cell transplantation. The results showed that CMML patients had significantly worse survival rates, progression-free survival, and relapse rates compared to MDS patients, while non-relapse mortality did not differ significantly. This study demonstrates the poor outcomes of CMML patients after hematopoietic cell transplantation.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
